Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 Jan 2022

Kim Hyung-Don, Ryu Min-Hee, Park Young Soo, Lee Sun Young, Moon Meesun, Kang Yoon-Koo

Abstract excerpt

BACKGROUND: We aimed to investigate the clinical implications of the tumor mutation burden (TMB) and insertion-deletion (indel) rate in gastric cancer patients treated with nivolumab. METHODS: A total of 105 patients with advanced gastric cancer who were treated with nivolumab as third or later line of therapy were included as the study population. The indel rate was defined as the proportion of indels making up...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Gastric Cancer Management and Outcomes

Share to Lung Neoplasms

Share to Mutation

Share to Nivolumab

Share to Stomach Neoplasms

Source

Identifiers

PMID: 34468871
DOI: 10.1007/s10120-021-01233-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.PMID 34468871Read ↗

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerSemantic proximity Read ↗

The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.Semantic proximity Read ↗

Significance of Tumor Mutation Burden Combined With Immune Infiltrates in the Progression and Prognosis of Advanced Gastric CancerSemantic proximity Read ↗

Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach AdenocarcinomaSemantic proximity Read ↗

Influence of Tumor Mutational Burden on Immune-infiltrating Cells in Stomach AdenocarcinomaSemantic proximity Read ↗

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapySemantic proximity Read ↗

Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).Semantic proximity Read ↗

Impact of Age on Tumor Mutation Burden in Gastric patients:a secondary analysis based on a cross-sectional studySemantic proximity Read ↗

Alterations in Intratumoral Immune Response Before and Early-on-Treatment of Nivolumab in Unresectable Advanced or Recurrent Gastric CancerSemantic proximity Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer.Semantic proximity Read ↗

Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.